logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

MNSO (09896) repurchased 100,000 shares on October 29 for HK$1.904 million.

date
17:53 29/10/2026
avatar
GMT Eight
MINISO (09896) announced that on October 29, 2026, the company repurchased 100,000 shares for HK$1.904 million.
MNSO (09896) announced that on October 29, 2026, the company repurchased 100,000 shares for HK$1.904 million.
Related Articles
HK Stock
SINOHYTEC (02402) reported a net loss attributable to shareholders of approximately RMB187 million for the first three quarters, narrowing by about 40% year-on-year.
US Stock
Merck & Co., Inc. (MRK.US) Q3 results beat expectations: Keytruda and Gardasil perform well, full-year guidance raised.
HK Stock
MICROTECH MED-B (02235) repurchased 1,800 shares on October 29 for approximately HK$12,100.
SINOHYTEC (02402) reported a net loss attributable to shareholders of approximately RMB187 million for the first three quarters, narrowing by about 40% year-on-year.
HK Stock
Merck & Co., Inc. (MRK.US) Q3 results beat expectations: Keytruda and Gardasil perform well, full-year guidance raised.
US Stock
MICROTECH MED-B (02235) repurchased 1,800 shares on October 29 for approximately HK$12,100.
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.